Cardax, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CDXI research report →
About the company
Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and marketing nutritional supplements for maintaining inflammatory well-being, as well as developing pharmaceutical treatments for chronic ailments rooted in inflammation and oxidative stress. Its product portfolio includes ZanthoSyn, an advanced supplement for inflammation, health, and longevity that delivers astaxanthin with superior absorption and purity.
- CEO
- David G. Watumull
- IPO
- 2013
- Employees
- 10
- HQ
- Honolulu, HI, US
Price Chart
- Market Cap
- $80
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -1.81
- Div Yield
- 0.00%
- Gross Margin
- 63.61%
- Op Margin
- -568.26%
- Net Margin
- -938.04%
- ROE
- 58.12%
- ROIC
- 57.33%
- Revenue
- $538.95K · -24.19%
- Net Income
- $-5,055,507 · 0.74%
- EPS
- $-6.79 · 19.17%
- Op Income
- $-3,062,636
- FCF YoY
- 49.61%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -13.76
- Avg Volume
- 22.664
Get TickerSpark's AI analysis on CDXI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 24, 14 | PAULSON CAPITAL (DELAWARE) CORP. | buy | 500,000 |
| Feb 24, 14 | Paulson Cardax Investments 1 LLC | buy | 500,000 |
| Feb 7, 14 | Paulson Cardax Investments 1 LLC | other | 1,068,477 |
| Feb 7, 14 | PAULSON CAPITAL (DELAWARE) CORP. | other | 1,068,477 |
| Feb 7, 14 | PAULSON CAPITAL (DELAWARE) CORP. | other | 0 |
| Feb 7, 14 | PAULSON CAPITAL (DELAWARE) CORP. | other | 0 |
| Feb 7, 14 | PAULSON CAPITAL (DELAWARE) CORP. | other | 3,872,434 |
Our CDXI coverage
Recent articles, reports, and earnings notes.
No research on CDXI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CDXI report →Similar companies
Peers in the same neighborhood.